Department of Radiology, Başkent University Hospital, Oymaci Sok. No. 7, Altunizade, Üsküdar, Istanbul, Turkey.
J Vasc Interv Radiol. 2011 Nov;22(11):1581-5. doi: 10.1016/j.jvir.2011.07.004. Epub 2011 Aug 16.
To determine the midterm technical and clinical results of endovascular occlusion of native hemodialysis fistulas with the use of the AMPLATZER Vascular Plug (AVP) I and AVP II.
Data from 21 patients who underwent endovascular occlusion of their native fistulas between March 2008 and October 2009 were retrospectively evaluated. The reasons for closing the fistulas were hyperdynamic heart failure (n = 2), venous aneurysm with skin ulceration and nipple formation with impending rupture (n = 5), central venous occlusion that could not be recanalized by an endovascular approach (n = 7), dialysis-associated steal syndrome (n = 2), and critical hand ischemia with a nonhealing ulcer or necrosis (n = 5).
All fistulas were embolized successfully by the end of the intervention. No procedure-related complications were observed after the intervention. The follow-up time ranged from 5 months to 24 months, with a mean of 13.5 months.
The results of this study suggest that the AVP is a safe and effective device for the endovascular occlusion of hemodialysis fistulas in selected cases.
评估使用 AMPLATZER 血管塞(AVP)I 和 AVP II 对自体血液透析瘘管进行血管内闭塞的中期技术和临床结果。
回顾性分析 2008 年 3 月至 2009 年 10 月期间 21 例患者行自体瘘管血管内闭塞的数据。闭塞瘘管的原因包括:高动力性心力衰竭(n=2)、伴皮肤溃疡和乳头形成即将破裂的静脉瘤(n=5)、经血管内途径无法再通的中心静脉闭塞(n=7)、透析相关窃血综合征(n=2)、伴未愈合溃疡或坏死的严重手部缺血(n=5)。
所有瘘管均在干预结束时成功栓塞。干预后无与操作相关的并发症。随访时间 5 至 24 个月,平均 13.5 个月。
该研究结果表明,在选择病例中,AVP 是一种安全有效的自体血液透析瘘管血管内闭塞的装置。